. https://decisionresourcesgroup.com/drg-blog/opdivo-falls-short-first-line-checkmate-026-nsclc-trial-will-repercussions-commercial-prospects/

home.aspx
   

article
SHARESHARESHARE
OPDIVO FALLS SHORT IN THE FIRST-LINE CHECKMATE-026 NSCLC TRIAL – WHAT WILL THE REPERCUSSIONS BE ON ITS COMMERCIAL PROSPECTS?
Last week Bristol-Myers Squibb (BMS) announced that CheckMate-026, a Phase III trial of Opdivo (nivolumab) in first-line non-small cell lung cancer (NSCLC) had failed to meet its primary endpoint of PFS in patients expressing PD-L1 on at least 5% of tumor cells (BMS Press Release, August 5, 2016). READ MORE